Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy

A legfontosabb adatok

Ki végzi
Johns Hopkins University
Hol
Szaúd-Arábia és Vietnám10 helyszín, 2 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Résztvevők
360 fő vett részt
Kezdés
2022. ápr. 15.
Befejezés
2025. jún. 7.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • GALAD Score
A regiszteradat frissítve
2025. június 12.
Miért állt le
PI moving on from current institution

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study and up to 5 years post-study follow up
  • Adults aged 18 or older
  • Both genders and all ethnicities
  • Willingness to give written, informed consent to be enrolled into the database
  • Collection of biosamples (serum, plasma, and urine) at each of the 6 months follow up during the study duration
  • Individuals already confirmed to have cirrhosis with MELD ≤ 15 from any etiology (chronic HBV, chronic HCV, NASH cirrhosis, etc.)
  • For chronic HBV and/or /HCV carrier, with or without on treatment
  • Reside in Vietnam or Saudi Arabia at the time of study and provides contact information (email and/or cell phone number for texting)
  • No prior or current treatment of HCC
  • No cancer history within 5 years
  • No participation in a trial for HCC Treatment
  • No prior solid organ transplant
  • Albumin, Bilirubin, Creatinine and INR labs within past 30 days
  • Imaging showing no HCC within 180 days
  • Diagnosis of fibrosis and cirrhosis based on: histology, image showing cirrhotic liver with splenomegaly and platelets <120 mm3, or esophageal or gastric varices on endoscopy AND presence of chronic liver disease/Fibroscan/Fib-4/APRI/ARFI. For viral hepatitis, kPa>=9kPa, APRI >=1; for NAFLD/NASH (FIB-4 > 1.3 \& TE > 8kPa)
  • No significant hepatic decompensation
  • No hepatorenal syndrome
  • AFP labs within 180 days irrespective of AFP titer
  • Two phone numbers and personal identification numbers (CMND number)
  • No known AIDS related diseases
  • No significant co-morbid conditions with life expectancy <5 years
  • No other cancer(s)

Ki nem vehet részt

  • On liver transplantation list or anticipated to be on the liver transplantation list during the study duration
  • Taking Vitamin K within 7 days prior to clinic follow or having disease affecting Vitamin K levels
  • Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements
  • Decompensated cirrhosis (variceal bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, and/or hepatorenal syndrome) or MELD>15
  • Any serious or active medical or psychiatric illness, which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol
  • Known HIV positive
  • Individuals who already have HCC, with or without HCC treatment
  • Individuals who cannot, do not want to, or refused to sign the informed consent form (ICF)
  • Documentation was not adequate

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study has two purposes. One is to conduct a phase IV biomarker validation study in which the investigators will prospectively survey a cohort of patients at risk for liver cancer using semi-annual abdominal ultrasound and GALAD Score for 5 years. The GALAD score is a serum biomarker-based panel that can aid in early detection among patients with a high risk for liver cancer. One is to establish a bio-repository of longitudinally collected bio-specimens from patients with fibrosis/cirrhosis as a reference set for future research.

A vizsgált kezelések

  • GALAD Score

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Surveillance and Treatment Of Primary Hepatocellular Carcinoma: An International Cohort Study of High-Risk Patients for HCC Using Liquid Biopsy
Publikációk
A regiszteradat frissítve
2025. június 12.